CLINICAL TRIALS PROFILE FOR METHYLNALTREXONE BROMIDE
✉ Email this page to a colleague
All Clinical Trials for methylnaltrexone bromide
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00401375 ↗ | Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI) | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 | 2006-10-31 | To evaluate the safety and efficacy of MNTX in participants who have undergone segmental colectomy and to assess if the time between the end of surgery and the first bowel movement is significantly shorter in the MNTX regimen than the equivalent assessment using a placebo regimen. |
| NCT00401375 ↗ | Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI) | Completed | Bausch Health Americas, Inc. | Phase 3 | 2006-10-31 | To evaluate the safety and efficacy of MNTX in participants who have undergone segmental colectomy and to assess if the time between the end of surgery and the first bowel movement is significantly shorter in the MNTX regimen than the equivalent assessment using a placebo regimen. |
| NCT00401375 ↗ | Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI) | Completed | Valeant Pharmaceuticals International, Inc. | Phase 3 | 2006-10-31 | To evaluate the safety and efficacy of MNTX in participants who have undergone segmental colectomy and to assess if the time between the end of surgery and the first bowel movement is significantly shorter in the MNTX regimen than the equivalent assessment using a placebo regimen. |
| NCT00547586 ↗ | Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain | Completed | Progenics Pharmaceuticals, Inc. | Phase 2 | 2007-10-01 | The primary purpose of this study is to evaluate the safety and dose-response relationship of N-methylnaltrexone bromide (MOA-728) by observing spontaneous bowel movements in subjects with chronic pain, which is not due to malignant cancer, and who have opioid-induced bowel dysfunction (OIBD). |
| NCT00547586 ↗ | Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain | Completed | Bausch Health Americas, Inc. | Phase 2 | 2007-10-01 | The primary purpose of this study is to evaluate the safety and dose-response relationship of N-methylnaltrexone bromide (MOA-728) by observing spontaneous bowel movements in subjects with chronic pain, which is not due to malignant cancer, and who have opioid-induced bowel dysfunction (OIBD). |
| NCT00547586 ↗ | Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain | Completed | Valeant Pharmaceuticals International, Inc. | Phase 2 | 2007-10-01 | The primary purpose of this study is to evaluate the safety and dose-response relationship of N-methylnaltrexone bromide (MOA-728) by observing spontaneous bowel movements in subjects with chronic pain, which is not due to malignant cancer, and who have opioid-induced bowel dysfunction (OIBD). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for methylnaltrexone bromide
Condition Name
Clinical Trial Locations for methylnaltrexone bromide
Trials by Country
Clinical Trial Progress for methylnaltrexone bromide
Clinical Trial Phase
Clinical Trial Sponsors for methylnaltrexone bromide
Sponsor Name
